CGP 39393

Known as: CGP-39393 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
1996
Highly Cited
1996
BACKGROUND The frequency of thromboembolism after major orthopaedic surgery continues to be high despite prophylaxis. New agents… (More)
  • table 1
  • table 4
  • table 2
  • table 3
  • table 5
Is this relevant?
1994
1994
Hirudin is an anticoagulant originally extracted from the leech Hirudo medicinalis. Using recombinant DNA technology a new… (More)
Is this relevant?
1994
1994
SummaryTen healthy male volunteers not previously exposed to hirudin participated in an open trial to evaluate the effects on… (More)
Is this relevant?
1993
1993
OBJECTIVES The purpose of this study was to investigate the biologic efficacy and pharmacokinetics of different doses of… (More)
  • table 1
  • figure 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
1993
1993
Clinical pharmacology of the intravenously administered recombinant desulfatohirudin CGP 39393 was investigated in 47 healthy… (More)
Is this relevant?
1993
1993
The infusion of a high dose of recombinant desulphatohirudin HVI (CGP 39393) for 40 min at 30 micrograms/kg/min, resulted in a… (More)
Is this relevant?
1990
1990
We studied the inhibitory action of recombinant desulphatohirudin (CGP 39393) on thrombin generation in whole plasma. Human… (More)
  • figure I
  • figure 1
  • figure 4
Is this relevant?
1990
1990
The aim of this study was to compare the ability of standard heparin and recombinant (r-)hirudin, a specific inhibitor of… (More)
Is this relevant?
1989
1989
The effects of the newly available biotechnology product, recombinant desulphatohirudin (CGP 39393) have been investigated in… (More)
Is this relevant?